Hook:
Over the past 7 days, Baichuan AI lost its entire founding team. Not a single co-founder remains. The company that raised 50 billion RMB ($700M) at a 200 billion valuation just shredded its general-purpose LLM roadmap. No more scaling law wars. No more API revenue. No more chasing GPT-4o. The new playbook: medical AI, a vertical so narrow it makes a DePIN project look like a layer-1.
Speed is the only currency that never inflates. And Baichuan just redeployed its stack at maximum velocity. But here’s the raw signal: when a unicorn pivots this hard, it tells you the crypto-AI convergence is not about general intelligence — it’s about survival disguise.
Context:
Baichuan AI was the poster child for China’s LLM boom. Founded by Wang Xiaochuan (former Sogou CEO), it raised from Alibaba, Tencent, and insurance giants. Its Baichuan series models cracked the top 10 in domestic benchmarks. Then the music stopped. By late 2024, the model was being outpaced by Qwen, DeepSeek, and Yi. The API revenue never materialized. The enterprise sales cycle was brutal. Meanwhile, the team splintered — co-founders pushed for AI coding agents (think Cursor, Copilot) or continued scaling. Wang chose the knife: cut the general model, cut enterprise, cut R&D for 100-billion-parameter pre-training. Go all-in on medical.
This is not a pivot. It’s a amputation. And the financials are stark: 50 billion RMB is a lot of capital, but in medical AI it buys 5-8 NMPA certifications at best. The burn rate? Probably 1-2 billion per month for a 300-person team. That’s 24 months max. The clock is ticking.
Core:
Here’s the technical signal the market is missing. Baichuan’s medical product, the M4 large model, will likely be fine-tuned from its existing Baichuan base, not retrained from scratch. That means no new massive compute requirements. The M4 inference cost? Probably $0.03 per query — cheap enough for a doctor’s assistant but not for a consumer app. The “family doctor agent” Baixiaoyi is an agentic wrapper around this fine-tuned model. No autonomous trading, no on-chain execution. Just text-based Q&A.
But the real story is the infrastructure bleed. Baichuan had already pre-committed to cloud contracts with Alibaba Cloud for thousands of GPUs. Those contracts are now worth less than 20% utilization. Asset impairment is coming. And the GPU inventory — A100s, H800s — will flood the secondary market. In crypto terms, this is like a major miner shutting down a farm. The hashpower is being redistributed. For decentralized compute networks (Akash, io.net), this could mean lower GPU leasing costs in 2025 Q3.
Commercialization is the gnarliest puzzle. Medical AI in China requires NMPA Class II or III certificates. Each application costs $5-10M in clinical trials. Baichuan has zero so far. Competitors like Shukun Technology already have Class III for multiple modalities. Baichuan’s edge? Natural language processing. They can generate medical reports, do patient triage, and summarize literature. But that’s a feature, not a moat. The big money is in imaging AI, which Baichuan cannot do without investing another $100M+ in computer vision specialists.
Governance isn’t. And here’s where the crypto angle tightens. Baichuan’s entire strategic shift mirrors what we saw in DeFi after the 2022 crash: generalist protocols (Uniswap, Curve) survived, but the highest-alpha plays were vertical (makerDAO, Aave’s stablecoin). The survivors didn’t try to be everything. They found a niche with regulatory friction — medical AI, like real-world asset tokenization, has the highest moat if you can clear compliance.
I don’t predict the market; I ride its heartbeat. And the heartbeat is telling me that Baichuan’s move is a massive signal for the crypto-AI sector. Expect a wave of AI projects pivoting from “general agent” to “vertical agent” in legal, medical, and supply chain. The narrative shift from scaling laws to compliance-first will dominate 2026 bear market discourse.
Contrarian:
The unreported angle? This pivot actually exposes the fragility of the “AI superintelligence” narrative in crypto. Projects like Bittensor, Fetch.ai, and SingularityNET have built entire token economies around general-purpose intelligence. If a well-funded centralized player like Baichuan cannot make general LLM work, what hope do decentralized networks have? The data and compute required for broad horizontal intelligence are too expensive, and the market is too competitive. The only sustainable path for crypto AI is ultra-specialized verticals — exactly what Baichuan is doing.
Furthermore, Baichuan’s founder conflict reveals a deep truth about team dynamics in crypto. Wang Xiaochuan overruled his co-founders on AI coding. That’s a single-founder decision in a multi-stakeholder environment. In DAO-governed AI projects, such a pivot would require a vote. The inefficiency could kill the project. Centralized speed wins again. Speed is the only currency that never inflates.
But here’s the counter: Baichuan is now a single-founder company with no experienced medical AI leadership. The CTO and medical product head are missing. The team is demoralized. The valuation ($200B) is inflated — comparable to a DeFi protocol with no TVL. If the next funding round is a down-round (likely at $100-150B), token holders in associated projects (like those using Baichuan’s dataset) could see their collateral drop.
Takeaway:
Watch for three signals over the next 6 months: (1) Does Baichuan announce an NMPA application for M4? (2) Does it hire a Chief Medical Officer from a top-10 hospital? (3) Does it partner with a blockchain health data platform? If yes, the pivot is real. If no, it’s a slow liquidation. The bear market rewards survivors, not visionaries. Baichuan just bet everything on a vertical where the exit is either acquisition by Tencent Health or zero. I’m watching the heartbeat. Are you?
